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Abstract 
This paper presents and compares for the first time two chiral LC-QTOF-MS methodologies 
(utilising CBH and Chirobiotic V columns with cellobiohydrolase and vancomycin as chiral 
selectors) for the quantification of amphetamine, methamphetamine, MDA 
(methylenedioxyamphetamine), MDMA (methylenedioxymethamphetamine), propranolol, 
atenolol, metoprolol, fluoxetine and venlafaxine in river water and sewage effluent. The 
lowest MDLs (0.3-5.0 ng L
-1
 and 1.3-15.1 ng L
-1
 for river water and sewage effluent 
respectively) were observed using the chiral column Chirobiotic V. This is with the exception 
of methamphetamine and MDMA which had lower MDLs using the CBH column. However, 
the CBH column resulted in better resolution of enantiomers (Rs = 2.5 for amphetamine 
compared with Rs = 1.2 with Chirobiotic V). Method recovery rates were typically >80% for 
both methodologies. Pharmaceuticals and illicit drugs detected and quantified in 
environmental samples were successfully identified using MS/MS confirmation. In sewage 
effluent, the total beta-blocker concentrations of propranolol, atenolol and metoprolol were on 
average 77.0, 1091.0 and 3.6 ng L
-1
 thus having EFs (Enantiomeric Fractions) of 0.43, 0.55 
and 0.54 respectively. In river water, total propranolol and atenolol was quantified on average 
at <10.0 ng L
-1
. Differences in EF between sewage and river water matrices were evident: 
venlafaxine was observed with respective EF of 0.43±0.02 and 0.58±0.02. 
Keywords 
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1.0 Introduction 
Complete removal of pharmacologically active a compounds is rarely achieved by sewage 
treatment processes, as these are biological treatment systems designed to reduce the level of 
organic substances found in domestic sewage. The incomplete removal of pharmacologically 
active compounds during sewage treatment results in their sustained emission to the aquatic 
environment (Ternes 1998; Hirsch, Ternes et al. 1999; Jones, Voulvoulis et al. 2001; Jones, 
Voulvoulis et al. 2002; Calamari, Zuccato et al. 2003; Glassmeyer, Furlong et al. 2005; Jones, 
Voulvoulis et al. 2007; Kasprzyk-Hordern, Kondakal et al. 2010). Once in the environment, 
trace levels of some compounds have been demonstrated to have adverse effects upon aquatic 
organisms. Previous research has focused upon compounds such as estrogens (Servos, Bennie 
et al. 2005; McAdam, Bagnall et al. 2010; Racz and Goel 2010) which have been 
demonstrated to cause feminisation of fish, or fluoxetine which has been shown to accumulate 
in fish tissue (Chu and Metcalfe 2007). Resultantly, a burgeoning field of research and 
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numerous methodologies for the analysis of pharmacologically active compounds within the 
aquatic environment has developed (Andreozzi, Raffaele et al. 2003; Hilton and Thomas 
2003; Hernando, Petrovic et al. 2004; Quintana, Rodil et al. 2004; Castiglioni, Bagnati et al. 
2005; Balakrishnan, Terry et al. 2006; Kasprzyk-Hordern, Dinsdale et al. 2007; Batt, Kostich 
et al. 2008; Berset, Brenneisen et al. 2010; Nödler, Licha et al. 2010; Baker and Kasprzyk-
Hordern 2011; López-Serna, Petrović et al. 2011). However, none of the above methods have 
the capability to resolve chiral drugs. This is surprising considering that approximately 56% 
of the pharmaceuticals currently in use are chiral and 88% of these are administered in 
racemic proportions (Lien Ai, Hua et al. 2006). 
Growing evidence of stereoselectivity in the aquatic environment demonstrates a need for the 
monitoring of chiral compounds. Fono and Sedlak (Fono and Sedlak 2005) reported racemic 
proportions of propranolol (EF, 0.49 - 0.54) in sewage influent but not in effluent (EF, 0.31-
0.44). In agreement with this, Nikolai et al. (Nikolai, McClure et al. 2006) reported 
enantioselective biodegradation of atenolol, metoprolol and propranolol during sewage 
treatment. Kasprzyk-Hordern et al. (Kasprzyk-Hordern, Kondakal et al. 2010) studied several 
pharmaceuticals and drugs of abuse including amphetamine, methamphetamine, MDMA and 
venlafaxine during wastewater treatment and observed their non-racemic composition 
following treatment. Recently in a profiling study of chiral drugs in wastewater and receiving 
water, it was observed that stereoselectivity was dependent upon the type of chiral drug, 
treatment technology used and season (Kasprzyk-Hordern and Baker 2011). 
The stereospecific distribution of chiral pharmaceuticals in the environment is an important 
consideration, particularly in terms of ecotoxicity. In a recent review, it was suggested that 
single enantiomers of chiral drugs should be considered as separate contaminants due to their 
differing ecotoxicity within the aquatic environment (Kasprzyk-Hordern 2010). In a study of 
the sub-lethal effects of the antidepressant fluoxetine on aquatic vertebrates and invertebrates, 
it has been observed that S-fluoxetine was more toxic to Pimephales promelas than R-
fluoxetine (Stanley, Ramirez et al. 2007). However, these authors did not observe the same 
response for Daphnia magna. The authors suggest that different stereospecific responses may 
have resulted from different physiology between these two species and the closer homology 
between mammals and fish could indicate a potential hazard to humans. There is limited data 
on stereospecific toxicity of chiral drugs as currently toxicity of chiral drugs is only 
determined in racemic form. The work of Stanley et al. (Stanley, Ramirez et al. 2007) would 
indicate that this is an inaccurate means of assessment. If this is the case, then it would no 
longer be sufficient to monitor racemic concentrations of common chiral drugs.  
Consideration of the implications of chiral drugs within the aquatic environment is still in its 
infancy. Few methods exist for the analysis of chiral drug in environmental matrices 
(Matamoros and Bayona 2006; Nikolai, McClure et al. 2006; MacLeod, Sudhir et al. 2007; 
Barreiro, Vanzolini et al. 2010; Kasprzyk-Hordern, Kondakal et al. 2010; Hashim and Khan 
2011). Therefore the reliability of current chiral methods for the analysis of environmental 
matrices needs further critique. For example, the Chirobiotic V column with vancomycin as a 
chiral selector (supplied by Sigma-Aldrich) is widely used for the chiral separation in blood 
plasma (Siluk, Mager et al. 2007; Kingback, Josefsson et al. 2010; Zuo, Wo et al. 2010). Yet 
in application with environmental matrices, only MacLeod et al. (MacLeod, Sudhir et al. 
2007) utilised the Chirobiotic V column for the quantification of single enantiomers of nine 
compounds, including: the beta-blockers, atenolol, metoprolol and propranolol and the 
antidepressant fluoxetine.  
The aim of this research was to develop, validate and evaluate highly sensitive and selective 
multi-residue methodology for the analysis of chiral compounds at enantiomeric levels in 
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river water and sewage effluent. Samples were analysed using a QTOF mass spectrometer in 
full scan mode and confirmed with MS/MS. This method of analysis allows for retrospective 
screening and verification of analytes in the form of new and emerging contaminants and their 
transformation pathways in the environment. To the authors’ knowledge, this is the first 
report discussing the application of HPLC-QTOF instrumentation for separation of chiral 
drugs at enantiomeric level with the usage of two chiral columns (Chirobiotic V and CBH). 
This paper compares and contrasts the method parameters (such as linearity, resolution, 
detection/quantification limits and recovery rates) for these two columns. This paper hopes to 
contribute to a new but rapidly expanding area of analytical chemistry. 
 
2.0 Materials and Methods 
2.1 Chemicals and Reagents 
The reference standards: R/S (±)-amphetamine, S (+)-amphetamine, R/S (±)-
methamphetamine, S (+) methamphetamine, R/S (±)-MDA and R/S (±)-MDMA were 
purchased from LGC Standards (UK): R/S (±)-venlafaxine; R/S (±)-fluoxetine; S (+)-
fluoxetine; R/S (±)-atenolol; R/S (±)-metoprolol and R/S (±)-propranolol were purchased 
from Sigma-Aldrich (UK). All solvents were of HPLC grade and purchased from Sigma-
Aldrich. All glassware was silanised with dimethylchlorosilane (5% DMDCS in toluene, 
Sigma–Aldrich) to minimise sample loss through adsorption of basic analytes onto OH-sites 
present on glass surface. The internal standards (IS): R/S (±)-amphetamine-d11, R/S (±)-
methamphetamine-d14, R/S (±)-MDMA-d5, R/S(±)-MDA-d5 were purchased from LGC 
standards, whilst R/S(±)-fluoxetine-d5 and R/S(±)-atenolol-d7 were purchased from Sigma-
Aldrich. All internal standards were added to the samples before solid-phase extraction (SPE) 
and upon preparation of calibration standards. Stock solutions of each compound (1 mg mL
-1
) 
were prepared in methanol and stored in the dark at −16 ◦C. Working solutions were prepared 
by diluting stock solution in mobile phase and stored at 4 
◦
C. Ultrapure water (UP) obtained 
with PURELAB UHQ-PS Unit (Elga, UK), river water (collected from the River Avon, 
Salford, Somerset) and wastewater (collected from a local WWTP) were used for method 
validation. 
2.2 Sample Collection, Preparation and Solid-Phase Extraction 
River water was collected from the River Avon (Salford, Somerset) during July and October. 
Wastewater was collected from a wastewater treatment work during July. For both river water 
and wastewater, each sample was collected into 1 L polypropylene bottles and stored on dry-
ice. Prior to solid-phase extraction (SPE), samples were filtered through Whatman GF/F 0.7 
µm glass fibre filters (Whatman, UK). The SPE procedure was based on methodology 
described elsewhere (Kasprzyk-Hordern, Dinsdale et al. 2007; Kasprzyk-Hordern, Kondakal 
et al. 2010). In brief, HLB cartridges were preconditioned with 2 mL of methanol followed by 
2 mL of water at a flow rate of <3 mL min
-1
. 250 mL of the previously filtered river water 
samples, or 100 mL of sewage effluent, was spiked with mixed racemic standard containing 
the following IS (50 ng of each enantiomer): R/S (±)-amphetamine-d11; R/S (±)-
methamphetamine-d14; R/S (±)-MDMA-d5; R/S (±)-MDA-d5; R/S (±)-fluoxetine-d5 and R/S 
(±)-atenolol-d7. The sample was then passed through the cartridge at a flow rate of <6 mL 
min
-1
. Analytes were eluted with 4 mL of methanol at a rate of <1 mL min
-1
. Extracts were 
then evaporated to dryness with a TurboVap evaporator (Caliper, UK, 40 ºC, N2, <5 psi) and 
reconstituted in 0.5 mL of mobile phase. All samples were filtered through 0.2 µm PTFE 
filters (Whatman, Puradisc, 13mm) and transferred to polypropylene 0.3 mL capacity vials 
(Waters, UK). In addition to IS (spiked at 200 and 500 ng L
-1
 for river water and sewage 
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effluent respectively), matrix was spiked, with a methanolic stock solution containing a 
racemic mix of chiral compounds at 50, 100 or 200 ng L
-1
 for river water and 250, 2500 or 
5000 ng L
-1
 for sewage effluent and were extracted according to the procedure described 
above. Three extractions were carried out for each concentration and each extract was injected 
into the HPLC-QTOF in triplicate. 
2.3 Chromatographic and Analytical Conditions 
Two multi-residue methods are described here, both utilising an ACQUITY UPLC system 
(Waters, UK) and a micrOTOFQ (Quadrupole, Time-of-Flight) mass spectrometer (Bruker 
Daltoniks GmbH, Germany). Two chiral columns were utilised: (i) a Chiral-CBH column, 
100 x 2 mm, I.D. 5µm (Chromtech, UK) and Chiral-CBH 10 x 2.0 mm, I.D. 5µm guard 
column (Chromtech, UK), and (ii) a Chirobiotic V column, 250 x 2.1 mm, I.D. 5µm (Sigma-
Aldrich, UK) and 20 x 1.0 mm, I.D. 5 µm guard column (Sigma-Aldrich, UK). 
The Chiral-CBH method was based on methodology of Kasprzyk-Hordern et al. (Kasprzyk-
Hordern, Kondakal et al. 2010). Separation was undertaken using isocratic conditions, with a 
mobile phase of 90 % H2O, 10 % 2-propanol and 1 mM ammonium acetate at a flow rate of 
0.075 mL min
-1
. The apparent pH of the mobile phase was 7. The column was maintained at 
25 ºC, the autosampler temperature was 4 ºC, with an optimal chromatographic run time of 65 
minutes and the injection volume was 20 µL.  
The Chirobiotic V method also used isocratic conditions. Several mobile phases were studied 
in order to obtain chiral separation and to maintain satisfactory electrospray ionisation (ESI) 
performance in positive mode. These included: methanol, acetonitrile, 2-propanol and water 
used either as the key constituent of the mobile phase or as a blend. Mobile phase additives 
included ammonium acetate and formic acid, which were added at concentrations ranging 
from 1 to 10 mM and 0.1 to 0.005 % respectively. Flow rates between 0.075–0.2 mL min-1 
were studied. The optimised chromatographic conditions for this column were: methanol 
containing 4 mM ammonium acetate and 0.005 % formic acid at a flow rate of 0.1 mL min
-1
. 
The column was maintained at 25 ºC, the autosampler temperature was 4 ºC, with an optimal 
chromatographic run time of 40 minutes, the injection volume was 20 µL.  
A micrOTOFQ mass spectrometer equipped with an electrospray ionization source was used 
for chiral drug identification and quantification. Analyses were performed in positive ion 
mode with a capillary voltage of 4.5 kV, end plate offset of -500 V; the nebuliser gas pressure 
was 2.0 bar, and dry gas flow of 8 L min
-1
, with a dry gas temperature of 200°C. Nitrogen was 
used as the nebulising gas, provided by a high purity nitrogen generator (Parker Hannifin Ltd, 
UK). Argon (99.999%) was used as the collision gas during MS/MS experimentation. Hystar 
software (Bruker Daltonik GmbH) was used to control the Waters ACQUITY system and the 
micrOTOFQ. Data was processed using DataAnalysis v4.0 and QuantAnalysis v4.0 (Bruker 
Daltonik GmbH).  
2.4 Elution Order of Enantiomers 
The elution order of atenolol, metoprolol and venlafaxine enantiomers has previously been 
established for a Chirobiotic V column under similar chromatographic conditions was used 
during this study (Liu, Wang et al. 2007; MacLeod, Sudhir et al. 2007). The elution order of 
atenolol, amphetamine, methamphetamine, MDA and MDMA has also been previously 
determined for the CBH column (Kasprzyk-Hordern and Baker 2011). The elution order for 
amphetamine, methamphetamine and fluoxetine using the Chirobiotic V column was 
determined experimentally using single enantiomeric standards and subsequent comparison 
with racemic standards. 
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2.5 Method Validation 
Identification of the target compounds was carried out using accurate mass measurements. 
Subsequent quantification of chiral drugs was carried out by a 13-point multi-component 
internal standard calibration curve (0-500 µg L
-1
) produced by serial dilution of a stock 
solution of compounds (1 mg L
−1
). The calibration curve was prepared by calculating the 
ratios between the peak area of each substance and the peak area of the internal standard and 
was used to determine linearity, range and instrumental detection and quantification. Compass 
QuantAnalysis software was used to analyse and process all data. The instrument quantitation 
limit (IQLS/N) was estimated for the concentration of compound that gave a signal-to-noise 
ratio of 10:1. The instrument detection limit (IDLS/N) corresponded to the concentration that 
gave a signal-to-noise ratio of 3.3:1. Method detection limits (MDL) and method 
quantification limits (MQL) for river water and sewage effluent were calculated using Eq. 1 
and 2. 
CFRR
IDL
MDL



100
           (1)
 
CFRR
IQL
MQL



100
          (2)
 
MDL = method detection limit 
MQL = method quantification limit 
IDL = instrumental detection limit  
IQL = instrumental quantification limit 
RR = recovery rate  
CF = concentration factor (500 for river water, 200 for sewage effluent). 
Method validation parameters such as accuracy and precision were determined using 
calibration standards (50 and 500 µg L
-1
). These were injected in triplicate each day over a 
three-day period. Accuracy of the method was assessed as the percentage deviation from the 
known amount of analyte added to the sample. Precision was evaluated as the relative 
standard deviation (RSD) of replicate measurements. Both intra- and inter-day 
reproducibilities of the analytical method were determined.  
Resolution (Rs) was determined using Eq. 3, over three concentrations in standards (50, 100 
and 200 µg L
-1
), river water (50, 100 and 200 ng L
-1
) and sewage effluent (250, 2500 and 
5000 ng L
-1
) for both Chirobiotic V and CBH methods. 
 
5.0
2
5.0
1
12177.1
bb
RtRt
Rs



         (3)
 
Rs = resolution 
Rt1 and Rt2 = retention times of the first and second eluting enantiomers respectively 
1
b0.5 and 
2
b0.5 = the peak widths of the first and second eluting enantiomers at half height 
Enantiomeric fraction (EF) was calculated using Eq. 4 over the calibration range for each 
compounds for both Chirobiotic V and CBH methods with both absolute and relative 
(normalised with internal standard) peak areas. 
))()((
)(



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E
EF
          (4)
 
EF = enantiomeric fraction  
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E(+) = the peak area of the (+) enantiomer  
E(-) = peak area of the (-) enantiomer.  
In the case where elution order was not known, the following Eq.5 was used. 
)21(
1
EE
E
EF

           (5) 
E1 = the peak area of the first eluting enantiomer 
E2 = peak area of the second eluting enantiomer.  
 
3 Results and Discussion 
3.1 The Chiral Separation of Drugs with Chirobiotic V and CBH columns 
The aim of this investigation was to develop and compare two new methods for multi-residue 
separation of chiral drugs in environmental matrices using two chiral columns (Chirobiotic V 
and CBH) and Acquity UPLC-QTOF instrumentation.  The Chirobiotic V column with 
vancomycin as a chiral selector utilises wide-ranging interactions including hydrogen and 
hydrophobic bonding, ionic, π-π, dipole and steric interactions and is therefore applicable for 
compounds with a broad range of physicochemical properties. Enantiomeric resolution of 
≥1.0 indicating maximum 2% overlap, which is required for quantitative analysis, was 
achieved with the Chirobiotic V column for amphetamine, methamphetamine, MDMA, 
atenolol, metoprolol, propranolol, venlafaxine and fluoxetine (Table 1).  
The CBH column with cellobiohydrolase as a chiral selector possesses multiple chiral centres 
of one configuration as well as mechanisms for ionic, hydrophobic and hydrogen bonding that 
contribute to the retention process. It is designed primarily for the chiral separation of 
compounds containing one or more nitrogen atoms in addition to one or more hydrogen 
donating or accepting groups, thus allowing for enantiomeric resolution of ≥1.0 for a smaller 
group of compounds. These included amphetamine, methamphetamine, MDA, MDMA, 
atenolol and venlafaxine (Table 2).  
In general, the CBH column provided much better resolution for all amphetamine-like 
compounds, than the Chirobiotic V column. For example, Rs for amphetamine enantiomers 
was 2.1 in the case of the CBH column and only 1.1 in the case of the Chirobiotic V column 
(Tables 1 and 2). In the case of MDMA, Rs was on average >1.9 for the CBH column and 
only 1.0 in the case of the Chirobiotic V column. Baseline resolution of MDA enantiomers 
was obtained in the case of the CBH column (Rs, >3.1), while this proved to be impossible 
with the Chirobiotic V column (Rs, <0.4). The CBH column was also more selective towards 
certain beta-blockers than the Chirobiotic V column, the Rs for atenolol being on average 7.3 
in the case of the CBH column, and only 1.9 for the Chirobiotic V column. Very strong and 
selective interactions between propranolol and the CBH column, resulted in very long 
retention times (>90 min). Therefore the Chirobiotic V column was found to be a better 
choice for the analysis of this compound at enantiomeric level. 
The Chirobiotic V column proved to be more selective than CBH column for antidepressants 
(fluoxetine and venlafaxine). For example, baseline separation of venlafaxine and fluoxetine 
was recorded for the Chirobiotic V (Rs = >4.3 and >2.2 respectively). The CBH column 
allowed for good separation of venlafaxine (Rs = 0.9 - 1.0) and no satisfactory separation of 
fluoxetine. 
The study showed that the impact from environmental matrix appeared to have little effect 
upon enantiomer resolution. The reproducibility of resolution of enantiomers over three 
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concentrations in standards (50, 100 and 200 µg L
-1
), river water (50, 100 and 200 ng L
-1
) and 
sewage effluent (250, 2500 and 5000 ng L
-1
) was consistent for both the Chirobiotic V and 
CBH column methods (Table 1 and 2). The inter-concentration RSD of Rs for both methods 
was ≤11% in both standards and environmental matrices. This was with the exception of 
metoprolol and propranolol in sewage effluent matrix (Chirobiotic V column method) which 
had average inter-concentration Rs of 1.6±0.4 (RSD = 22.9 %) and 2.2±0.4 (RSD = 18.7 %) 
respectively. Examples of enantiomeric resolution in spiked river water are detailed for the 
Chirobiotic V and CBH columns respectively in Figures 1 and 2.  
3.2 Method Validation  
Linearity and limits of detection data are presented in Tables 1 and 2. Average linearity for all 
compounds showed R
2
 of 0.997 using both the Chirobiotic V and CBH columns. The IDL and 
IQL for the Chirobiotic V column ranged from <0.3 – 4.0 µg L-1 and 0.5 – 15.0 µg L-1. 
Furthermore excluding MDMA, the MDL and MQL for river water matrices ranged from 
<0.2 – 5.5 ng L-1 and <0.3 – 18.5 ng L-1 respectively (Table 1). The MDL and MQL for 
sewage effluent matrices, excluding MDMA, ranged from 0.6 – 14.2 ng L-1 and 1.3 – 47 ng L-
1
 respectively (Table 1). In comparison, the IDL and IQL for CBH were typically higher, 
ranging respectively from 1.25– 5 µg L-1 and 5 – 25 µg L-1 (Table 2), probably as the CBH 
mobile phase was 90% aqueous and would have caused lower MS signal in comparison to 
that of the Chirobiotic V method utilising organic mobile phase. MDMA was an exception as 
it was found to have slightly lower IQL with the CBH column method (12.5 µg L
-1 
for both 
enantiomers) than with the Chirobiotic V column (15.0 µg L
-1
 for both enantiomers). 
Furthermore, the MQL in river water for MDMA separated with the CBH column was lower 
(R (-) = 26.8 and S (+) = 25.6 ng L
-1
) when compared to the Chirobiotic V column (E1 = 85.7 
and E2 = 81.9 ng L
-1
). In comparison with triple-quadrupole analysers, which have better 
sensitivity due to analysis of targeted fragmentation ions, the IDL/IQLs presented here were 
unsurprisingly higher. Kasprzyk-Hordern et al. (Kasprzyk-Hordern, Kondakal et al. 2010) 
reported IDLs for amphetamine, methamphetamine, MDA and MDMA of 0.025 – 0.1 µg L-1. 
However, the advantages of utilising QTOF over triple-quadrupole analysers include the 
screening for non-target metabolites and break-down products that can be carried out. High 
throughput analytical techniques employing QTOF are developing into important tools for the 
analysis of environmental matrices (Ibanez, Sancho et al. 2008; Helbling, Hollender et al. 
2010; Hernandez, Bijlsma et al. 2011). Studies such as these demonstrate that in order to 
progress research in this field, it is necessary to analyse a broader range of compounds in 
addition to their metabolites and microbial transformation products.  
The detection limits of this study, although higher than in the cases utilising triple 
quadrupoles, are comparable or lower than other analytical methodologies utilising QTOF. 
For example, in a multi-residue (non-chiral) method for 29 pharmaceuticals using HLB SPE 
methodology with Acquity UPLC coupled to a QTOF-Micro (Waters Corp., USA) IDLs 
ranged from 0.5 – 10 µg L-1 (Petrovic, Gros et al. 2006). These authors observed IDLs of 1, 
0.2 and 2 µg L
-1
 for atenolol, metoprolol and propranolol respectively. During this study 
(Table 1), the IDLs for atenolol, metoprolol and propranolol were 1.2, 0.3 and 0.3 µg L
-1
 
respectively (for individual enantiomers) using the Chirobiotic V method. Furthermore, 
Petrovic et al. (Petrovic, Gros et al. 2006) observed MDLs of 50, 15 and 100 ng L
-1
 for 
atenolol, metoprolol and propranolol respectively in sewage influent. In this study, the MDLs 
were lower for sewage effluent using the Chirobiotic V column and were: 5.3 and 5.0 ng L
-1
 
for S (-) and R (+) atenolol respectively; 0.6 and 0.7 ng L
-1 
enantiomers of metoprolol 
respectively and 1.0 and 1.4 ng L
-1 
in the case of S (-) and R (+) propranolol respectively.  
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The enantiomeric fractions of all studied compounds for both methodologies are detailed in 
Table 3 and were calculated using Equations 4 and 5. Upon calculation of absolute EF (based 
upon peak areas of the target compound alone), deviation from 0.5 indicating racemic solution, 
could be witnessed with both methodologies. This was particularly evident with amphetamine 
(absolute EF 0.58±0.08 and 0.57±0.05 for Chirobiotic V and CBH respectively). The absolute 
EF for atenolol was 0.54±0.03 and 0.43±0.06 for Chirobiotic V and CBH respectively. 
Normalising peak areas with internal standard resulted in relative EFs that were closer to 0.5. 
Precision and accuracy data for the Chirobiotic V and CBH column methodologies are 
detailed in Tables 4 and 5. Over three days and across the range of concentrations tested (50 – 
500 µg L
-1
) intra-day and inter-day precision was on average 4.6 and 7.7 % respectively for 
the Chirobiotic V column, which was similar to the CBH column intra-day and inter-day 
precision over three-days (on average 5.7 and 7.6 % respectively). Over three days and across 
the range of concentrations assessed, intra-day and inter-day accuracy was on average 90 % 
and 91 % respectively for the Chirobiotic V column. For the CBH column, over three days 
intra-day and inter-day precision were both higher, on average 101 %. Recovery rates for 
spiked river water matrices were typically >80 % for both the Chirobiotic V and CBH column 
methodologies (Table 6). Recovery rates for spiked sewage effluent matrices were 
comparable to those of river water and were typically ~80 %, over the range of spiked 
concentrations.  
In summary, although the accuracy of LC-chiral-QTOF has been demonstrated to be less than 
equivalent LC-chiral-quadrupole methodology (MacLeod, Sudhir et al. 2007; Kasprzyk-
Hordern, Kondakal et al. 2010), overall precision and accuracy was suitable for environmental 
analysis, given the complexity of the matrices. Application of the correct chiral column and 
applying recovery correction, meaningful quantification of environmental matrices could be 
performed. The findings of this study suggest that the Chirobiotic V methodology can be used 
successfully for the quantification of amphetamine, methamphetamine, metoprolol, 
propranolol, fluoxetine, atenolol, metoprolol and venlafaxine in environmental matrices. 
Furthermore the CBH methodology can be used for the quantification of amphetamine, MDA, 
MDMA, atenolol, and venlafaxine in these same matrices. With the use of QTOF technology, 
retrospective and non-targeted analysis is achievable and is a distinct advantage over the use 
of triple-quadrupole mass spectrometers. QTOF-MS methodology could also be used to 
monitor for break-down products in conjunction with routine targeted analysis. 
3.3 The Identification and Confirmation of Chiral Drugs in the Environment using 
QTOF 
Using the CBH column method no chiral drugs were detected or quantified in river water 
matrix. The MQLs for this method were not as low as those when using the Chirobiotic V 
column. However, the Chirobiotic V method was capable of quantifying venlafaxine, 
propranolol and atenolol in both river and sewage effluent matrices (Table 7). In river water, 
the total concentration of propranolol was just below the MQL 1.7 ng L
-1
 and the EF was 0.45, 
this was within the range of propranolol concentrations and EFs reported by Fono and Sedlak 
et al. (Fono and Sedlak 2005). The concentration of total venlafaxine was just above the MQL 
(19.3 ng L
-1
) and the EF was 0.58. These results similar to Kasprzyk-Hordern and Baker 
(Kasprzyk-Hordern and Baker 2011) who reported near racemic proportions of venlafaxine in 
river water at a total concentration of 10 ng L
-1
. The average total concentration of atenolol 
was 30.0 ng L
-1
 and the EF was 0.47; and again falls within the range observed by Kasprzyk-
Hordern and Baker (Kasprzyk-Hordern and Baker 2011). Direct comparison for venlafaxine 
has not been possible as the order in which the enantiomers elute is not known for the CBH 
column method.  
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The concentrations of chiral drugs observed in sewage effluent are detailed in Table 7. In this 
matrix, the average total propranolol concentration was 77.0 ng L
-1
 and the EF was 0.43. This 
is in agreement with Fono and Sedlak et al. (Fono and Sedlak 2005) who reported EF ranging 
from 0.31 to 0.44 and MacLeod et al. (MacLeod, Sudhir et al. 2007) who reported EF for 
propranolol of ~0.4. Average total venlafaxine concentration was 106.5 ng L
-1
 and EF 
constituted 0.43. Atenolol was recorded at the highest concentration of all compounds (931 ng 
L
-1
). The EF of this compound was 0.55. The E2 MDMA enantiomer was detected in sewage 
effluent at levels >MDL (19.9 ng L
-1
), however this concentration can only be viewed semi-
quantitatively. It is likely that E2 MDMA corresponds with R (-)-MDMA as Kasprzyk-
Hordern and Baker (Kasprzyk-Hordern and Baker 2011) found this enantiomer to be enriched 
during sewage treatment. Metoprolol was also detected at just above the MQL (3.6 ng L
-1
), 
the EF for this compound was 0.54. It is likely that E1 and E2 for metoprolol correspond 
respectively with the S (-) and R (+) stereoisomers; as metoprolol is structurally related to 
atenolol and propranolol which both elute in this order (Figure 1). 
It is demonstrated here that chiral pharmaceuticals and illicit drugs in the aquatic environment 
are non-racemic in proportion. Furthermore, there was a pronounced difference in EF between 
the same compound in sewage effluent and river water. For example, the enrichment of the 
respective S (-) and R (-) enantiomers of propranolol (EF=0.43±0.02) and venlafaxine 
(0.43±0.02) that was seen in sewage effluent was not witnessed in river water to the same 
degree. In fact, these compounds in river water were closer to racemic proportions, the 
greatest evidence for which being with venlafaxine that demonstrated slight enrichment of the 
S (+) enantiomer (0.58±0.02). Differences in EF between sewage and river water matrices 
were also evident with atenolol: respective EF of 0.55±0.00 and 0.47±0.02 was observed. 
These observations could indicate that stereo-selective mechanisms during sewage treatment 
are different from those occurring in the aquatic environment. 
Quantification of chiral pharmaceuticals and drugs was done on an accurate mass basis; 
therefore further confirmation using MS/MS was desirable. The parameters utilised to achieve 
MS/MS spectra are detailed in Table 8. The MS/MS spectra obtained for venlafaxine, 
propranolol and atenolol in pure standard, river water and sewage effluent are detailed in 
Figure 3. Confirmation was done based on purity, fit and reverse fit (Equation 6, 7 and 8) 
using Bruker Data Analysis software. Comparison of ion ratios as per confirmation criteria of 
Council Directive 96/23/EC was also conducted (of 12 August 2002). 
UL
A
P
2
100
          (6)
 
TL
A
F
2
100
          (7)
 
UR
A
R
2
100
          (8)
 
 
Where: 
A=∑ of the product of the intensities of the unknown and the library spectrum 
U=∑ of the square of the intensities of the unknown spectrum 
L=∑ of the square of the intensities of the library spectrum 
T=∑ of the square of the intensities of the unknown spectrum where the library spectrum has 
intensity above 0 
R=∑ of the square of the intensities of the library spectrum where the unknown spectrum has 
intensity above 0 
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In both river water and sewage effluent P, F and R scores for propranolol and atenolol were 
>70% (Table 9), which has been suggested to be an acceptable threshold for trace analysis 
using library matching (Hopley, Bristow et al. 2008). The presence of E2 MDMA in sewage 
effluent could also be confirmed, as the P, F and R scores were 98 (Figure 4). Metoprolol was 
only detected in sewage effluent, matching scores for this compound were low (P = 52 and R 
= 53) for E1 (Table 9; Figure 4) and E2 metoprolol failed to match at all. Poor matching is 
likely to be have been contributed to by the low concentration of the compound in the 
environmental samples thus influencing the calculation matching scores as a result of signal 
noise (Pihlainen, Sippola et al. 2003). For venlafaxine, whilst P, F and R scores were >78% in 
river water, P scores were 46 and 59% for the S (+) and R (-) respectively. This could have 
been due to the isolation width of the collision cell which was ±3Da for the generation of 
MS/MS spectra. Thus compounds of similar mass derived from river water and sewage 
effluent could have contributed to these spectra. Furthermore, there was a statistical difference 
between the P, F and R scores of each enantiomer (ttest p<0.05). The P, F and R scores were 
higher for the R (-) venlafaxine in both river water and sewage effluent. This could indicate 
more co-eluting compounds where entering the collision cell with the S (+) enantiomer than 
the R (-).  
The presence of venlafaxine and metoprolol in sewage effluent as well as further confirmation 
of the other compounds was done by comparison of ion ratios between environmental 
samples and a 100 µg L
-1
 standard (Table 10) as per Council Directive 96/23/EC criteria (of 
12 August 2002). For example, the ion ratio between the first and second fragmentation ions 
for venlafaxine was 1.31. In river water this ion ratio was 1.27 for S (+) and 1.39 for R (-) and 
represents a deviation from that of the standard of -3.05 and 6.11 % respectively. Similarly in 
sewage effluent, the deviation from that of the standard was 7.63 % for both enantiomers. In 
fact all compounds had ion ratios between the first and second fragmentation ions that 
deviated <20 % from the 100 µg L
-1
 standard. These ions ratios could therefore be used as 
unique identifiers for confirmation of the compounds analysed here.  
 
4.0 Conclusion 
The effective application of a chiral HPLC-QTOF-MS methodology has been demonstrated 
for the analysis of environmental matrices, achieving resolution typically >1.0 for both 
methods. Using the Chirobiotic V or CBH column methodologies amphetamine, 
methamphetamine, MDA, MDMA, propranolol, atenolol, metoprolol, fluoxetine and 
venlafaxine could be quantified in environmental matrices. The Chirobiotic V column method 
gave lower MDLs for more compounds, however, precision and accuracy were comparable 
and were <8 % and >90 % respectively for both methodologies. Recoveries in river water and 
sewage effluent were typically >80 %. The Chirobiotic V methodology was used successfully 
for the quantification of amphetamine, methamphetamine, metoprolol, propranolol, fluoxetine, 
atenolol, metoprolol and venlafaxine in environmental matrices. Furthermore the CBH 
methodology can be used for the quantification of amphetamine, MDA, MDMA, atenolol, 
and venlafaxine in the same matrices. Subsequently, atenolol and venlafaxine were quantified 
in river water, showing average total concentrations of 30.1 and 19.3 ng L
-1
 respectively. 
Furthermore EF for atenolol and venlafaxine were 0.47 and 0.58 indicating slight enrichment 
of the S (-) and S (+) enantiomers respectively. In river water propranolol was detected just 
below the MDL. In sewage effluent, propranolol, atenolol, metoprolol and venlafaxine were 
quantified with average total concentrations of 77.0 and 1090.7, 12.6 and 106.5 ng L
-1
 
respectively. The EF for propranolol, atenolol, metoprolol and venlafaxine were 0.43, 0.55, 
0.54 and 0.43 respectively, thus indicating that the river environment effects change in ratio 
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for chiral drugs. The presence of pharmaceuticals and illicit drugs detected and quantified in 
environmental samples were successfully confirmed using MS/MS confirmation. In sewage 
effluent E2-MDMA (likely to be R (-)-MDMA) was detected just below the MDL. The use of 
a QTOF mass spectrometer has distinct advantages over quadrupole analysers as this 
methodology could also be used to monitor break-down products and be used for non-target 
screening in conjunction with routine targeted quantification.  
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Table 1. The method validation parameters for chiral drugs using Chirobiotic V including linearity, resolution, detection and quantification limits. 
 
Compound 
 
Instrumental Parameters River Water Sewage Effluent 
aRt 
(mins) 
Linearity range 
bR2 
cIDLs/n 
dIQLs/n 
eRs 
fMDLcalc 
gMQLcalc Rs MDLcalc MQLcalc Rs 
µg L-1 µg L-1 µg L-1 
50  
µg L-1 
100 
µg L-1 
200 
µg L-1 
ng L-1 ng L-1 
25 
ng L-1 
50 
ng L-1 
100 
ng L-1 
ng L-1 ng L-1 
25 
ng L-1 
250 
ng L-1 
500 
ng L-1 
Amphetamine S (+) 22.2 0.5-500 0.999 1.0 2.6 1.2 
±0.1 
1.1 
±0.1 
1.2 
±0.1 
1.8 4.8 1.3 
±0.1 
1.2 
±0.1 
1.3 
±0.1 
4.4 11.5 1.2 
±0.1 
1.2 
±0.0 
1.2 
±0.1 
R (-) 23.4 0.5-500 0.996 1.0 2.7 1.8 5.0 4.6 12.4 
Methamphetamine S (+) 31.2 0.25-500 0.999 3.0 10.0 1.1 
±0.0 
1.1 
±0.0 
1.2 
±0.3 
5.5 18.3 1.3 
±0.0 
1.3 
±0.1 
1.1 
±0.0 
14.2 47.3 1.2 
±0.0 
1.0 
±0.1 
0.9 
±0.0 
R (-) 32.6 0.25-500 0.999 2.5 10.0 4.6 18.5 11.9 47.6 
MDMA E1 35.4 5-500 0.997 4.0 15.0 1.0 
±0.1 
1.1 
±0.0 
1.0 
±0.0 
9.6 35.8 0.9 
±0.0 
0.9 
±0.0 
0.9 
±0.0 
22.8 85.7 1.0 
±0.0 
1.0 
±0.1 
0.9 
±0.0 
E2 37.0 5-500 0.994 4.0 15.0 10.4 39.0 21.8 81.9 
Propranolol S (-) 24.4 h0.25-100/5-500 h0.999/0.995 0.2 0.5 2.4 
±0.0 
2.3 
±0.1 
2.0 
±0.1 
0.4 1.2 2.3 
±0.1 
2.4 
±0.1 
2.1 
±0.1 
1.0 2.6 2.7 
±0.1 
2.2 
±0.2 
1.8 
±0.0 
R (+) 27.1 h0.25-100/5-500 h0.999/0.992 0.3 0.6 0.6 1.4 1.4 3.4 
Atenolol S (-) 35.0 h0.5-100/5-500 h0.998/0.998 1.2 2.5 2.0 
±0.1 
1.9 
±0.0 
1.8 
±0.1 
2.2 4.7 1.8 
±0.1 
1.9 
±0.1 
1.8 
±0.1 
5.3 11.0 1.8 
±0.0 
1.8 
±0.2 
1.6 
±0.0 
R (+) 38.2 h0.25-100/5-500 h0.998/0.999 1.1 2.5 2.1 4.8 5.0 11.4 
Metoprolol E1 22.1 h0.25-100/5-500 h0.999/0.993 0.3 0.5 1.8 
±0.1 
1.6 
±0.0 
1.4 
±0.1 
0.2 0.4 2.0 
±0.1 
1.8 
±0.1 
1.6 
±0.1 
0.6 1.3 2.1 
±0.1 
1.5 
±0.1 
1.3 
±0.1 
E2 24.0 h0.25-100/5-500 h0.998/0.992 0.3 0.5 0.2 0.3 0.7 1.3 
Venlafaxine S (+) 28.9 h0.25-100/5-500 h0.993/0.999 1.0 3.8 4.4 
±0.2 
4.6 
±0.2 
4.3 
±0.1 
2.2 8.1 3.8 
±0.1 
4.3 
±0.0 
3.9 
±0.0 
3.9 14.4 4.7 
±0.0 
4.2 
±0.0 
3.8 
±0.0 
R (-) 34.6 h0.25-100/5-500 h0.995/0.999 1.2 3.8 2.5 7.9 4.8 15.1 
Fluoxetine S (+) 32.9 h0.25-100/5-500 h0.999/0.996 0.4 1.0 2.4 
±0.1 
2.3 
±0.1 
2.2 
±0.1 
0.8 2.0 2.6 
±0.3 
2.5 
±0.1 
2.5 
±0.3 
2.6 6.5 2.5 
±0.1 
2.3 
±0.1 
2.2 
±0.0 
R (-) 36.1 h0.25-100/5-500 h0.999/0.996 0.4 1.3 0.8 2.5 2.4 7.6 
a Rt is the retention time, b R2 is the correlation coefficient, c IDLs/n is the instrumental detection limit based on signal to noise, 
d IQLs/n is the instrumental quantification limit based on signal to noise, 
e Rs is 
the chromatographic resolution, f MDLcalc is the calculated method detection limit, 
g MQLcalc is the calculated method quantification limit, 
h low and high range calibrations used due to lack on linearity of 
over the full range 
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Table 2. The method validation parameters for chiral drugs using CBH including linearity, resolution, detection and quantification limits. 
Compound 
a
Rt (mins) 
Instrumental Parameters 
  
River Water 
  Linearity range bR2 cIDLs/n 
d
IQLs/n eRs 
f
MDLcalc 
g
MQLcalc Rs 
µg L
-1
 
 
µg L
-1
 µg mL
-1
 25 µg L
-1
 50 µg L
-1
 100 µg L
-1
 ng L
-1
 ng L
-1
 25 ng L
-1
 50 ng L
-1
 100 ng L
-1
 
Amphetamine R (-) 28.9 0.5-500 0.996 2.5 5.0 2.1±0.1 2.2±0.0 1.9±0.1 4.8 9.7 2.5±0.2 2.4±0.3 2.5±0.4 
S (+) 33.9 0.5-500 0.995 2.5 5.0 5.0 10.0 
Methamphetamine R (-) 29.9 2.5-500 0.996 2.5 12.5 1.2±0.2 1.2±0.2 1.2±0.1 4.1 20.6 1.3±0.1 1.2±0.2 1.2±0.1 
S (+) 32.9 2.5-500 0.993 2.5 12.5 3.6 18.1 
MDA R (-) 43.5 1.75-500 0.998 1.25 5.0 3.1±0.3 3.4±0.2 3.2±0.2 2.4 9.6 3.3±0.4 3.4±0.2 3.2±0.2 
S (+) 52.8 1.75-500 0.998 1.25 5.0 2.3 9.1 
MDMA R (-) 40.2 12.5-500 0.995 5.0 12.5 2.7±0.5 1.9±0.1 1.9±0.1 10.7 26.8 3.1±0.2 2.3±0.2 2.2±0.1 
S (+) 46.7 12.5-500 0.996 5.0 12.5 10.2 25.6 
Atenolol R (+) 28.6 0.5-500 0.998 1.3 12.5 7.2±0.2 7.4±0.6 7.5±0.3 2.3 22.9 7.5±0.5 7.5±0.2 7.4±0.3 
S (-) 46.5 0.5-500 0.999 1.3 12.5 2.1 20.7 
Venlafaxine E1 28.4 5-500 0.995 5.0 25.0 0.9±0.1 0.9±0.1 1.0±0.1 10.3 51.7 0.9±0.1 0.9±0.1 1.0±0.1 
E2 30.8 5-500 0.997 5.0 25.0 9.6 47.9 
a Rt is the retention time, b R2 is the correlation coefficient, c IDLs/n is the instrumental detection limit based on signal to noise, 
d IQLs/n is the instrumental quantification limit based on signal to noise, 
e Rs is 
the chromatographic resolution, f MDLcalc is the calculated method detection limit, 
g MQLcalc is the calculated method quantification limit,  
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Table 3. The absolute and relative EF of calibration standard using Chirobiotic V and 
CBH methodologies 
Compound Chirobiotic V CBH 
 
c
Abs 
d
Rel Abs Rel 
Amphetamine 
a
0.58±0.08 
a
0.51±0.03 
a
0.57±0.07 
a
0.51±0.05 
Methamphetamine 
a
0.52±0.06 
a
0.54±0.06 
a
0.54±0.04 
a
0.49±0.03 
MDMA 
b
0.47±0.03 
b
0.49±0.03 
a
0.53±0.03 
a
0.51±0.04 
Propranolol 
a
0.54±0.04 
a
0.50±0.02   
Atenolol 
a
0.54±0.03 
a
0.51±0.01 
a
0.43±0.06 
a
0.51±0.04 
Metoprolol 
b
0.52±0.01 
b
0.54±0.02   
Venlafaxine 
a
0.49±0.03 
a
0.50±0.03 
b
0.46±0.04 
a
0.52±0.03 
Fluoxetine 
a
0.46±0.04 
a
0.49±0.04   
a
 EF calculated using Equation 4, 
b
 EF calculated using Equation 5, 
c Abs is the absolute EF, d Rel is the relative EF (peak 
areas are normalised using internal standards) 
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Table 4. The intra and inter-day precision (%) observed over three days using the Chirobiotic V and CBH columns 
Compound 
Intra-day precision (%) Inter-day precision (%) 
50 µg L
-1
 500 µg L
-1
 50 µg L
-1
 500 µg L
-1
 50 µg L
-1
 500 µg L
-1
 
Chirobiotic V CBH Chirobiotic V CBH 
Chirobiotic V CBH 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
Amphetamine S (+) 1 3 1 8 11 13 8 10 3 4 9 13 2 8 9 9 
R (-) 3 4 4 8 5 3 3 10 7 6 10 12 3 10 6 9 
Methamphetamine S (+) 5 4 2 7 11 11 6 6 3 1 1 3 7 6 10 4 
R (-) 4 5 4 9 9 3 6 3 2 4 7 7 7 9 9 9 
aVenlafaxine Chiro (S (+)) / CBH (E1) 2 2 4 3 2 4 7 3 2 2 3 4 9 14 6 5 
Chiro (R (-))/CBH (E2) 2 3 9 3 3 15 9 4 4 1 6 1 11 14 10 5 
Fluoxetine S (+) 6 5 1 - - - 5 5 3 - - - 6 7 - - 
R (-) 4 3 3 - - - 9 3 5 - - - 9 17 - - 
MDA S (+) - - - 9 1 6 - - - 4 3 3 - - 5 4 
R (-) - - - 6 3 3 - - - 5 6 6 - - 1 3 
bMDMA Chiro (E1)/CBH (S (+)) 4 5 3 10 8 9 7 4 7 7 6 4 9 10 15 5 
Chiro (E2)/CBH (R (-)) 2 6 7 10 3 9 5 20 17 3 8 4 10 16 11 5 
cMetoprolol E1 11 6 0 - - - 4 4 5 - - - 11 9 - - 
E2 9 9 4 - - - 3 3 1 - - - 11 2 - - 
Atenolol S (-) 2 0 5 7 5 4 2 1 6 2 2 2 3 4 7 11 
R (+) 4 4 5 5 7 4 3 4 2 2 2 1 5 5 6 4 
Propranolol S (+) 9 7 1 - - - 2 7 2 - - - 10 7 - - 
R (-) 7 5 3 - - - 2 1 2 - - - 8 2 - - 
a Elution order known only for Chirobiotic V. b Elution order only known for CBH. c Neither elution order is known for Chirobiotic V or CBH 
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Table 5. The intra and inter-day accuracy (%) observed over three days using the Chirobiotic V and CBH columns  
Compound 
Intra-day Accuracy (%) Inter-day Accuracy (%) 
50 µg L
-1
 500 µg L
-1
 50 µg L
-1
 500 µg L
-1
 50 µg L
-1
 500 µg L
-1
 
Chirobiotic V CBH Chirobiotic V CBH 
Chirobiotic V CBH 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
Amphetamine S (+) 104 100 100 109 107 103 103 114 109 114 103 115 101 109 106 112 
R (-) 100 98 97 112 103 108 87 93 80 123 122 119 98 87 108 122 
Methamphetamine S (+) 97 109 99 132 117 121 102 94 98 109 118 115 102 89 124 114 
R (-) 91 103 102 115 115 105 111 95 98 96 94 89 99 102 112 93 
a
Venlafaxine Chiro (S (+)) / CBH (E1) 90 81 75 76 78 68 128 109 96 94 97 90 82 113 74 94 
Chiro (R (-))/CBH (E2) 93 80 74 86 93 87 137 113 102 97 106 102 82 118 89 101 
Fluoxetine S (+) 101 104 111 - - - 76 73 82 - - - 105 77 - - 
R (-) 98 99 117 - - - 76 68 97 - - - 104 81 - - 
MDA S (+) - - - 115 115 114 - - - 106 107 110 - - 115 108 
R (-) - - - 108 108 108 - - - 101 102 102 - - 108 102 
b
MDMA Chiro (E1)/CBH (S (+)) 65 56 54 71 81 61 75 66 82 102 103 99 59 75 71 102 
Chiro (E2)/CBH (R (-)) 57 48 48 70 79 65 64 73 78 94 94 89 52 71 71 92 
c
Metoprolol E1 100 95 81 - - - 85 104 95 - - - 93 94 - - 
E2 104 93 86 - - - 99 102 99 - - - 95 100 - - 
Atenolol S (-) 94 90 94 120 112 127 85 80 81 101 88 113 92 82 119 101 
R (+) 87 85 91 97 101 107 83 76 83 94 92 101 88 81 102 96 
Propranolol S (-) 90 91 76 - - - 80 88 75 - - - 87 80 - - 
R (+) 84 90 78 - - - 88 87 85 - - - 85 87 - - 
a Elution order known only for Chirobiotic V. b Elution order only known for CBH. c Neither elution order is known for Chirobiotic V or CBH 
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Table 6. The average recovery rates (±%RSD) observed for the overall analytical protocol using Chirobiotic V or CBH (n=9).  
Compound 
Chirobiotic V CBH 
Enantiomer 
River Water Sewage Effluent 
Enantiomer 
River Water 
   Mean    Mean    Mean 
25 ng L
-1
 50 ng L
-1
 100 ng L
-1
 125 ng L
-1
 1250 ng L
-1
 2500 ng L
-1
 25 ng L
-1
 50 ng L
-1
 100 ng L
-1
 
Amphetamine E1 S (+) 105±8 110±2 113±6 109±7 109±3 115±3 114±4 113±4 E1 R (-) 101±10 101±10 108±7 104±9 
E2 R (-) 104±5 109±4 113±6 108±6 104±6 113±2 108±8 109±6 E2 S (+) 105±7 94±9 102±9 100±9 
Methamphetamine E1 S (+) 107±6 110±6 110±6 109±6 93±12 106±3 118±5 106±12 E1 R (-) 132±6 118±8 115±4 112±9 
E2 R (-) 104±8 111±7 110±6 108±8 97±13 103±6 115±7 115±14 E2 S (+) 138±12 138±6 138±7 138±8 
MDA E1  - - - - - - - - E1 R (-) 114±2 107±7 95±5 105±9 
E2  - - - - - - - - E2 S (+) 113±4 113±6 104±8 110±7 
MDMA E1  66±12 85±7 82±7 84±17 61±15 102±10 105±1 88±26 E1 R (-) 77±21 106±8 96±6 93±17 
E2  64±15 81±8 87±7 77±16 73±17 94±10 108±8 92±19 E2 S (+) 78±20 110±12 105±7 98±18 
Propranolol E1 S (-) 81±10 74±9 85±5 81±9 91±4 96±2 88±3 92±4   - - - - 
E2 R (+) 71±9 67±7 87±7 76±14 75±12 84±2 76±6 78±9   - - - - 
Atenolol E1 S (-) 95±4 104±4 120±5 107±11 108±1 116±4 115±7 113±5 E1 R (+) 116±6 112±9 102±3 109±9 
E2 R (+) 92±4 110±5 112±4 104±10 95±5 115±5 118±6 109±11 E2 S (-) 126±7 122±5 116±10 121±8 
Metoprolol E1  101±9 100±5 108±5 104±7 73±0 79±3 73±4 76±5   - - - - 
E2  116±8 113±3 107±4 112±7 87±10 77±3 65±5 75±13   - - - - 
Venlafaxine E1 S (+) 86±9 78±7 80±12 82±10 93±14 119±1 126±5 115±14 E1  90±10 79±10 87±11 85±11 
E2 R (-) 88±8 78±6 84±6 84±9 104±0 115±6 109±12 110±8 E2  99±13 88±13 87±11 85±11 
Fluoxetine E1 S (+) 83±10 90±5 106±5 90±12 67±10 64±5 76±6 69±10   - - - - 
E2 R (-) 92±21 93±5 82±12 89±15 86±20 67±9 73±6 74±15   - - - - 
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Table 7. Average concentration and EF (enantiomeric fraction) of chiral drugs observed in river water and sewage effluent (river water n=6, 
sewage effluent n=4) 
Compound 
July 2011 (Chirobiotic V) Oct 2011 (CBH) 
Enantiomer 
River water (ng L
-1
) Sewage effluent (ng L
-1
) 
Enantiomer 
River water (ng L
-1
) 
MQL Mean EF MQL Mean EF MQL Mean 
Amphetamine E1 S (+) 4.8 <MQL  11.5 <MQL  E1 R (-) 9.7 <MQL 
E2 R (-) 5.0 <MQL  12.4 <MQL  E2 S (+) 10.0 <MQL 
Methamphetamine E1 S (+) 18.3 <MQL  47.3 <MQL  E1 R (-) 20.6 <MQL 
E2 R (-) 18.5 <MQL  47.6 <MQL  E2 S (+) 18.1 <MQL 
MDA E1        E1  9.6 <MQL 
E2        E2  9.1 <MQL 
MDMA E1  35.8 <MQL  85.7 <MQL  E1  26.8 <MQL 
E2  39 <MQL  81.9 19.9±6.2  E2  25.6 <MQL 
Propranolol E1 S (-) 1.2 0.9±0.1 
a
0.45±0.04 2.6 46.5±2.5 
a
0.43±0.02     
E2 R (+) 1.4 0.8±0.1 3.4 30.5±5.9     
Atenolol E1 S (-) 4.7 15.8±1.3 
a
0.47±0.02 11 497.6±11.5 
a
0.55±0.00 E1 R (-) 22.9 <MQL 
E2 R (+) 4.8 14.2±1.4 11.4 593.1±22.9 E2 S (+) 20.7 <MQL 
Metoprolol E1  0.4 <MQL  1.3 1.7±0.1 
b
0.54±0.02     
E2  0.3 <MQL 1.3 1.9±0.1     
Venlafaxine E1 S (+) 8.1 10.8±0.8 
a
0.58±0.02 14.4 43.9±5.0 
a
0.43±0.02 E1  51.7 <MQL 
E2 R (-) 7.9 8.5±1.0 15.1 62.6±8.3 E2  47.9 <MQL 
Fluoxetine E1 S (+) 2.0 <MQL  6.5 <MQL      
E2 R (-) 2.5 <MQL 7.6 <MQL     
a
 EF calculated using Equation 4, 
b
 EF calculated using Equation 5 
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Table 8. The mass, mass accuracy and MS/MSMS parameters associated with the compounds of study 
Compound 
Formula 
Theoretical 
Mass 
Experimental 
Mass 
Error MSMS parameters 
 
[M] [M+H]
+
 [M+H]
+
 mDa ppm 
Isolation 
width 
Collision 
energy 
Internal Standard 
RS(±)-Amphetamine C9H13N 136.1121 136.1118 -0.3 -2.2 3 12 RS(±)-Amphetamine-d11 
RS(±)-Methamphetamine C10H15N 150.1277 150.1275 -0.2 -1.3 3 12 RS(±)-Methamphetamine-d14 
RS(±)-MDA C10H13NO2 180.1019 180.1019 0.0 0.0 3 9 RS(±)-MDA-d5 
RS(±)-MDMA C11H15NO2 194.1176 194.1208 3.2 16.5 3 12 RS(±)-MDMA-d5/RS(±)-MDA-d5 
RS(±)-Propranolol C16H21NO2 260.1645 260.1625 -2.0 -7.7 3 14 RS(±)-Atenolol-d7 
RS(±)-Atenolol C14H22N2O3 267.1703 267.1697 -0.6 -2.2 3 12 RS(±)-Atenolol-d7 
RS(±)-Metoprolol C15H25NO3 268.1907 268.1885 -2.2 -8.2 3 18 RS(±)-Atenolol-d7 
RS(±)-Venlafaxine  C17H27NO2 278.2115 278.2102 -1.3 -4.7 3 13 RS(±)-Methamphetamine-d14 
RS(±)-Norfluoxetine C16H16F3 NO 296.1257 296.1276 1.9 6.4 3 8 RS(±)-Fluoxetine-d5 
RS(±)-Fluoxetine C17H18F3NO 310.1413 310.1412 -0.1 -0.3 3 8 RS(±)-Fluoxetine-d5 
RS(±)-Amphetamine-d11 C9H2D11N 147.1811 147.1799 -1.2 -8.2 
   RS(±)-Methamphetamine-d14 C10HD14N 164.2156 164.2143 -1.3 -7.9 
   RS(±)-MDA-d5 C10H8D5NO2 185.1333 185.1326 -0.7 -3.8 
   RS(±)-MDMA-d5 C11H10D5NO2 199.1489 199.1511 2.2 11.0 
   RS(±)-Atenolol-d7 C14D7H15N2O3 274.2143 274.2135 -0.8 -2.9 
   RS(±)-Fluoxetine-d5 C17 D5H13F3NO 315.1727 315.1720 -0.7 -2.2 
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Table 9. Identification of target analytes using library matching by MS-MS spectra 
the Purity (P), Fit (F) and Reverse Fit (R) for the spectra are illustrated in Figures 3 
and 4. Spectra from matrix were compared against pure standard. 
Matrix Compound Enantiomer 
Match score 
Purity Fit 
Reverse 
fit 
River 
Water 
Venlafaxine S (+) 78 81 82 
R (-) 82 86 87 
S+R (±) 80 84 85 
Propranolol S (-) 79 89 83 
R (+) 75 86 78 
S+R (±) 80 87 82 
Atenolol S (-) 95 98 95 
R (+) 94 96 94 
S+R (±) 95 97 95 
Sewage 
effluent 
Venlafaxine S (+) 46 61 60 
R (-) 59 75 77 
S+R (±) 53 68 69 
Propranolol S (-) 85 94 89 
R (+) 81 92 85 
S+R (±) 89 94 90 
Atenolol S (-) 98 99 98 
R (+) 98 98 98 
S+R (±) 98 99 98 
Metoprolol E1 52 83 53 
E2 
a
n/m 
a
n/m 
a
n/m 
MDMA E1 <MDL <MDL <MDL 
E2 98 98 98 
a
 n/m = no match 
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Table 10. The MSMS confirmation parameters for river water and sewage effluent matrices using 
comparison of ion ratios of the precursor ion (P), the 1
st 
fragmentation ion (F1) and the 2
nd
 
fragmentation ion (F2).  Ion ratios in environmental samples were compared with that of the pure 
standard.  
Compound Enantiomer 
M/Z Ion Ratios 
Ion ratio deviation 
from the 100 µg L
-1
 
Standard (%) 
1st 
Fragmentation 
Ion 
2nd 
Fragmentation 
Ion 
100 µg L
-1
 
Standard 
River 
Water 
Sewage 
Effluent 
River 
Water 
Sewage 
Effluent 
F1:F2 F1:F2 F1:F2 F1:F2 F1:F2 
Venlafaxine S 
215.1418±0.01 121.0635±0.01 1.31 
1.27 1.41 -3.05 7.63 
 R 1.39 1.41 6.11 7.63 
 S+R 1.35 1.43 3.05 9.16 
Propranolol S 
183.0802±0.01 157.0636±0.01 1.89 
1.76 1.66 -6.88 -12.17 
 R 2.07 1.95 9.52 3.17 
 S+R 1.76 1.94 -6.88 2.65 
Atenolol S 
190.0860±0.01 145.0626±0.01 1.19 
1.09 1.16 -8.4 -2.52 
 R 1.12 1.16 -5.88 -2.52 
 S+R 1.1 1.16 -7.56 -2.52 
Metoprolol E1 
159.0798±0.01 133.0640±0.01 1.1 
 
1.06 
 
-4.09 
 
E2 
 
0.98 
 
-11.08 
 
E1+E2 
 
0.99 
 
-10.14 
MDMA E2 163.0718±0.01 135.0424±0.01 1.61   1.29   -20.06 
 
 
 
 
  
23 
 
 
 
 
Figure 1. HPLC-MS chromatograms of chiral drugs spiked into river water, extracted by SPE and 
analysed using the Chirobiotic V column (concentration 100 µg L-1, retention time is presented in 
minutes)  
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Figure 2. HPLC-MS chromatograms of chiral drugs spiked into river water, extracted by SPE and 
analysed using the CBH column (concentration 100 µg L-1, retention time is presented in minutes) 
A = successfully separated compounds, B = unsuccessfully separated compounds 
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Figure 3. The comparision of average MS/MS spectra derived from both enantiomers of chiral drugs against pure 100 µg L-1 standard 
of chiral drugs quantfied in river water and sewage effluent 
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Figure 4. The comparision of average MSMS spectra derived from both enantiomers for metoprolol and only E2 for MDMA against 
pure100 µg L-1 standard of chiral drugs detected in sewage effluent 
 
